Idioma:

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Baeten, Dominique ; Sieper, Joachim ; Braun, Jürgen ; Baraliakos, Xenofon ; Dougados, Maxime ; Emery, Paul ; Deodhar, Atul ; Porter, Brian ; Martin, Ruvie ; Andersson, Mats ; Mpofu, Shephard ; Richards, Hanno B

The New England journal of medicine, 2015-12, Vol.373 (26), p.2534-2548 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Autor: Baeten, Dominique ; Sieper, Joachim ; Braun, Jürgen ; Baraliakos, Xenofon ; Dougados, Maxime ; Emery, Paul ; Deodhar, Atul ; Porter, Brian ; Martin, Ruvie ; Andersson, Mats ; Mpofu, Shephard ; Richards, Hanno B
Assuntos: Adult ; Ankylosing spondylitis ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Arthritis ; Body weight ; Candidiasis ; Candidiasis - etiology ; Cardiovascular disease ; Clinical trials ; Crohn Disease - chemically induced ; Cytokines ; Double-Blind Method ; Drug dosages ; Drug therapy ; Female ; Heart attacks ; Humans ; Inflammatory diseases ; Inhibitor drugs ; Interleukin-17 - antagonists & inhibitors ; Intravenous administration ; Male ; Middle Aged ; Monoclonal antibodies ; Neutropenia ; Neutropenia - chemically induced ; Patients ; Psoriasis ; Response rates ; Rheumatic diseases ; Spondylitis ; Spondylitis, Ankylosing - drug therapy ; Suicides & suicide attempts ; Tumor necrosis factor-TNF
É parte de: The New England journal of medicine, 2015-12, Vol.373 (26), p.2534-2548
Descrição: In two placebo-controlled phase 3 trials, secukinumab, an anti–interleukin-17A monoclonal antibody, was effective in patients with ankylosing spondylitis. Adverse events associated with secukinumab included infections and neutropenia. Ankylosing spondylitis is a chronic, immune-mediated disease that is characterized by inflammation and new bone formation in the axial skeleton 1 , 2 and that often results in progressive, irreversible structural damage, disability, deterioration of functioning, and a reduced quality of life. 3 , 4 Therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is often insufficient to control symptoms, and there is no evidence that conventional disease-modifying antirheumatic drugs (DMARDs) are efficacious in axial disease. 5 Anti–tumor necrosis factor (TNF) therapy is currently recommended for patients with persistent disease activity despite conventional treatment. 5 In some patients, however, such therapy fails to achieve adequate disease control or has . . .
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Baeten, Dominique ; Sieper, Joachim ; Braun, Jürgen ; Baraliakos, Xenofon ; Dougados, Maxime ; Emery, Paul ; Deodhar, Atul ; Porter, Brian ; Martin, Ruvie ; Andersson, Mats ; Mpofu, Shephard ; Richards, Hanno B

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.